Framework for out-of-field dosimetry in photon radiotherapy: application to Hodgkin lymphoma

Maite Romero-Expósito¹,², Isidora Múñoz³, Ignacio N López-Martínez¹, Ignacio Espinoza³, Juliana Toma-Dasu²,4, Alexandru Dasu¹,5, Daniel Molin⁶, Beatriz Sánchez-Nieto³

¹The Skandion Clinic, Uppsala, Sweden. ²Oncology Pathology Department, Karolinska Institutet, Stockholm, Sweden. ³Pontificia Universidad Católica de Chile, Instituto de Física, Santiago, Chile. ⁴Medical Radiation Physics, Stockholm University, Stockholm, Sweden. ⁵Medical Radiation Sciences, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ⁶Experimental and Clinical Oncology, Dept of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Background
The improved outcome of radiotherapy (RT) treatments raises the awareness of long term effects, such as secondary cancers. This is of special interest for young patients, treated with a curative intent, a group where classical Hodgkin lymphoma (cHL) is common.

Purpose
The objective of this work is to present the implementation of a framework for cHL patients to evaluate the out-of-field doses related to secondary cancer risk.

Materials
- The framework (Fig. 1) consists of 2 integrated Matlab-based programs to process the dicom files of a RT plan exported from the TPS:
  - IS²aR (1) generates a virtual whole-body CT phantom using the original CT of the patient
  - P3D (2) evaluates peripheral photon dose in the virtual phantom from the number of MU, the prescription dose, the mean field size (from 50% isodose) and the out-of-field area (defined from the 5% isodose).
- The system was tested in cHL patients, treated with VMAT.

Conclusions
- The system provides organ doses within about 30 minutes per patient.
- DVHs provided by the computation platform can be subsequently used for secondary cancer risk estimations.

Acknowledgments
This project has received funding from Euratom's research and innovation programme 2019-20 under grant agreement no. 945196. Radiumhemmets Forskningsfonder (Sweden) is acknowledged for financial support.

References

Figure 1. Framework and execution times.